凝汽采暖两用机组特性刍议

凝汽采暖两用机组目前已得到广泛的应用,为了促进热电联产事业健康发展,本文介绍有关其特性的一些看法,供参考。     

充电器大功率变压器的设计

介绍开关电源高频大功率变压器设计的材料选择、计算方法和过程,并给出了一个充电器大功率变压器的设计实例,实验证明该变压器符合实际要求。     

MIL-100(Fe) Sub-Micrometric Capsules as a Dual Drug Delivery System

Nanoparticles of metal–organic frameworks (MOF NPs) are crystalline hybrid micro- or mesoporous nanomaterials that show great promise in biomedicine due to their significant drug loading ability and controlled release. Herein, we develop porous capsules from aggregate of nanoparticles of the iron carboxylate MIL-100(Fe) through a low-temperature spray-drying route. This enables the concomitant one-pot encapsulation of high loading of an antitumor drug, methotrexate, within the pores of the MOF NPs, and the collagenase enzyme (COL), inside the inter-particular mesoporous cavities, upon the formation of the capsule, enhancing tumor treatment. This association provides better control of the release of the active moieties, MTX and collagenase, in simulated body fluid conditions in comparison with the bare MOF NPs. In addition, the loaded MIL-100 capsules present, against the A-375 cancer cell line, selective toxicity nine times higher than for the normal HaCaT cells, suggesting that MTX@COL@MIL-100 capsules may have potential application in the selective treatment of cancer cells. We highlight that an appropriate level of collagenase activity remained after encapsulation using the spray dryer equipment. Therefore, this work describes a novel application of MOF-based capsules as a dual drug delivery system for cancer treatment.     

一次220 kV保护误动作检查及处理

保护装置应定期检查,保证良好的运行工况。在条件允许的情况下,故障录波器的设置有利于故障分析、查找故障原因。     

X80级管线钢管和感应加热弯管的开发

分析了X80级管线钢管的试制开发及其在西气东输二线的应用情况,通过试验论证了X80级管线钢管的强度、韧性指标的可靠性。部分工程应用证明,该类管线钢管达到了高压输气管线的要求,且可节约管线工程的建设成本。提出了下一步需要继续研究的管线钢管问题,并对X80高频加热弯管的试制及性能做了简要分析。     

基于岩心核磁共振实验数据确定阳离子交换容量

以HSK方程为基础,提出了一种利用岩心核磁共振实验数据计算阳离子交换容量Qv的方法.该方法与湿式化学阳离子交换容量分析法相比存在一定的误差.12块岩样数据显示,相对误差范围12％～95％,平均相对误差为55％.分别从溶液矿化度、核磁共振总孔隙度以及黏土束缚水T2截止值等参数出发,开展了核磁共振确定阳离子交换容量影响因素分析研究.黏土束缚水T2截止值是影响核磁共振计算阳离子交换容量的关键参数,黏土束缚水T2截止值是可变的,而不是传统意义上的3 ms.基于岩心核磁共振准确求取阳离子交换容量的前提是准确求取黏土束缚水T2截止值.     

基于DSP的双频超声波流量计硬件电路设计

超声波流量测量技术是一种利用超声波信号在流体中传播时所载流体的流速信息来测量流体流量的新的测量技术,他具有非接触式测量、测量精度高、测量范围宽、安装维护方便等特点,特别适合用于临时管道流量、大口径管道流量以及危险性流体流量的测量。本文介绍了一种采用数字信号处理技术的双频超声波流量计的硬件电路设计方法。     

Functional and Structural Insights into Human PPARα/δ/γ Subtype Selectivity of Bezafibrate,Fenofibric Acid,and Pemafibrate

Among the agonists against three peroxisome proliferator-activated receptor (PPAR) subtypes, those against PPARα (fibrates) and PPARγ (glitazones) are currently used to treat dyslipidemia and type 2 diabetes, respectively, whereas PPARδ agonists are expected to be the next-generation metabolic disease drug. In addition, some dual/pan PPAR agonists are currently being investigated via clinical trials as one of the first curative drugs against nonalcoholic fatty liver disease (NAFLD). Because PPARα/δ/γ share considerable amino acid identity and three-dimensional structures, especially in ligand-binding domains (LBDs), clinically approved fibrates, such as bezafibrate, fenofibric acid, and pemafibrate, could also act on PPARδ/γ when used as anti-NAFLD drugs. Therefore, this study examined their PPARα/δ/γ selectivity using three independent assays—a dual luciferase-based GAL4 transactivation assay for COS-7 cells, time-resolved fluorescence resonance energy transfer-based coactivator recruitment assay, and circular dichroism spectroscopy-based thermostability assay. Although the efficacy and efficiency highly varied between agonists, assay types, and PPAR subtypes, the three fibrates, except fenofibric acid that did not affect PPARδ-mediated transactivation and coactivator recruitment, activated all PPAR subtypes in those assays. Furthermore, we aimed to obtain cocrystal structures of PPARδ/γ-LBD and the three fibrates via X-ray diffraction and versatile crystallization methods, which we recently used to obtain 34 structures of PPARα-LBD cocrystallized with 17 ligands, including the fibrates. We herein reveal five novel high-resolution structures of PPARδ/γ–bezafibrate, PPARγ–fenofibric acid, and PPARδ/γ–pemafibrate, thereby providing the molecular basis for their application beyond dyslipidemia treatment.